Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44334   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2019-004053-91
    Sponsor's Protocol Code Number:CO19/121741
    National Competent Authority:UK - MHRA
    Clinical Trial Type:EEA CTA
    Trial Status:GB - no longer in EU/EEA
    Date on which this record was first entered in the EudraCT database:2020-05-15
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedUK - MHRA
    A.2EudraCT number2019-004053-91
    A.3Full title of the trial
    Brain Re-Irradiation Or Chemotherapy: a phase II randomised trial of re-irradiation and chemotherapy in patients with recurrent glioblastoma
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    BRIOChe: A trial looking at re-irradiation and chemotherapy in patients with recurrent glioblastoma.
    A.3.2Name or abbreviated title of the trial where available
    BRIOChe
    A.4.1Sponsor's protocol code numberCO19/121741
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorUniversity of Leeds
    B.1.3.4CountryUnited Kingdom
    B.3.1 and B.3.2Status of the sponsorNon-Commercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportThe Jon Moulton Charity Trust
    B.4.2CountryUnited Kingdom
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationClinical Trials Research Unit, Leeds Institute of Clinical Trials Research
    B.5.2Functional name of contact pointUniversity of Leeds
    B.5.3 Address:
    B.5.3.1Street AddressWorsley Building
    B.5.3.2Town/ cityLeeds
    B.5.3.3Post codeLS2 9JT
    B.5.3.4CountryUnited Kingdom
    B.5.4Telephone number01133431486
    B.5.5Fax number01133431471
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Information not present in EudraCT
    D.2.1.1.1Trade name Lomustine medac
    D.2.1.1.2Name of the Marketing Authorisation holdermedac, Gesellschaft für klinische Spezialpräparate mbH, Theaterstr. 6, 22880 Wedel, Germany
    D.2.1.2Country which granted the Marketing AuthorisationGermany
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameLomustine
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNLomustine
    D.3.9.1CAS number 13010-47-4
    D.3.9.4EV Substance CodeAS1
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number40
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 2
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Information not present in EudraCT
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameProcarbazine
    D.3.4Pharmaceutical form Capsule
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNProcarbazine
    D.3.9.1CAS number 366-70-1
    D.3.9.3Other descriptive nameN-(1-Methylethyl)-4-[(2-methylhydrazinyl)methyl]benzamide hydrochloride
    D.3.9.4EV Substance CodeAS2
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number50
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.IMP: 3
    D.1.2 and D.1.3IMP RoleComparator
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation Information not present in EudraCT
    D.2.1.1.1Trade name Vincristine
    D.2.1.1.2Name of the Marketing Authorisation holderHospira UK Limited, Horizon, Honey Lane, Hurley, Maidenhead, SL6 6RJ
    D.2.1.2Country which granted the Marketing AuthorisationUnited Kingdom
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameVincristine
    D.3.4Pharmaceutical form Injection
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPIntravenous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNVincristine
    D.3.9.1CAS number 2068-78-2
    D.3.9.3Other descriptive name 22-Oxovincaleukoblastine sulfate salt, Leurocristine sulfate salt, VCR, Vincristine sulfate
    D.3.9.4EV Substance CodeAS3
    D.3.10 Strength
    D.3.10.1Concentration unit mg/ml milligram(s)/millilitre
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number1
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Recurrent Glioblastoma
    E.1.1.1Medical condition in easily understood language
    Brain tumour
    E.1.1.2Therapeutic area Diseases [C] - Cancer [C04]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10018336
    E.1.2Term Glioblastoma
    E.1.2System Organ Class 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The principal research question is to assess the number of patients alive in the re-irradiation arm at 9 months post-start of treatment. Overall survival will be defined as the time from randomisation to the date of death from any cause. OS rates in the chemotherapy arm will also be assessed for calibration purposes only and not for direct statistical comparison.
    E.2.2Secondary objectives of the trial
    Secondary endpoints will assess Health Related Quality of Life (HRQOL), using the European Organisation for Research and Treatment of Cancer (EORTC) Quality of Life (QLQ-C30) and Brain Cancer module (BN20) questionnaires, which will be completed by participants. Additionally, HRQOL will be also assessed by a one-off semi-structured interview in a participant/caregiver subset of 15 participants or until data saturation.
    Other secondary endpoints include Dexamethasone use, anti-epileptic drug use, radiological response rate, acute and late toxicities, overall survival (OS) and progression free survival (PFS).

    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    • Histologically proven diagnosis of GBM with consistent molecular pathology, based on original pathology.
    • First recurrence of GBM, with contrast enhancing disease, following primary treatment (or following surgery alone for first recurrence of GBM; i.e. no previous systemic therapy or re-irradiation for recurrence permitted).
    • The MRI scan that reveals recurrence must be reviewed by the local multi-disciplinary meeting, including agreement of a Consultant Neuro-Radiologist that imaging changes are in keeping with recurrence and not pseudo-progression.
    • Randomisation must be performed within 21 days of the MRI that confirms recurrence. Outside of 21 days, an updated MRI is required to confirm eligibility and serve as a contemporaneous baseline scan to assess response to further treatment. Please see section 9 Assessments for further details for achieving this.
    • ≥6 months since completion of primary radiotherapy (where the interval since radiotherapy completion is 5 months and 2 weeks or greater, this may be rounded up to 6 months and the patient included in the trial).
    • Prior history of standard dose, conventionally fractionated CNS radiotherapy (i.e. 54-60Gy in 28-33 fractions).
    • As a minimum patients will have completed at least two weeks of temozolomide, concurrent with their original radiotherapy.
    • Up to and including three enhancing lesions:
    - In cases of a single recurrent enhancing lesion:
    -predicted re-irradiation GTV<75cm3 (based on diagnostic MR imaging and on maximum diameters of enhancing disease in all 3 planes, calculated from 4/3π x ½ x diameter 1 x ½ x diameter 2 x ½ x diameter 3, and
    -maximum diameter of enhancing disease must be ≤6cm. In cases where there is circumferential enhancement around a cavity, such that the cavity and enhancing disease will be included in the GTV, then the maximum diameter of enhancing disease and cavity must be ≤6cm.
    -In cases of multiple (i.e. two or three) discrete recurrent enhancing lesions:
    -the total (i.e. combined) predicted re-irradiation GTV must be <50cm3 and lesions must be clustered in a similar brain region such that PTVs are anticipated to be adjacent or overlapping, and
    -maximum diameter of combined enhancing disease, across all enhancing lesions (including any gaps between), must be ≤6cm.
    • Karnofsky Performance Status 70+
    • Adequate hematologic, renal, and hepatic function (absolute neutrophil count, ≥1.5 x 109/L; platelet count, ≥100 x 109/L; White cell count ≥3.0 x 109/L; haemoglobin ≥10g/L (may be corrected by transfusion); serum creatinine clearance (measured or estimated) ≥30ml/min; total serum bilirubin level <1.5 times ULN; and ALT <5 times ULN) within 14 days prior to randomisation. (Dose modifications may still be required based on these parameters). Lymphopaenia is not a contra-indication to trial entry.
    • Patients who have had surgery for first recurrence may also be included provided there is residual enhancing disease on the immediate post-operative MRI or if enhancing disease develops on subsequent follow-up imaging, provided no prior systemic therapy or re-irradiation for recurrence has been given. As above, this MRI must be reviewed within the local multi-disciplinary meeting, with agreement of a Consultant Neuro-Radiologist that the imaging changes are in keeping with residual or new enhancing disease. Randomisation must be performed within 21 days of the MRI that confirms recurrence. Outside of 21 days, an updated MRI is required to confirm eligibility and serve as a contemporaneous baseline scan to assess response to further treatment.
    Patients must have recovered from the prior effects of therapy:
    - There must be a gap of at least 28 days since completion of adjuvant temozolomide or any other systemic anti-cancer therapy and commencement of re-irradiation or nitrosourea-based chemotherapy (note randomisation may occur prior to this provided all other eligibility criteria are met and the gap is at least 28 days when the trial treatment commences).
    - Patients who receive resection for recurrence must have adequate wound healing and resolution of any significant meningocoele or any other cause of swelling in close proximity to the wound.
    • Medical history and physical examination, including CNS examination, must be performed within 14 days prior to randomisation.
    • Female participants of child-bearing potential must agree to be pregnancy screened prior to entering BRIOChe and before signing the main informed consent form.Male participants must agree to practice methods of contraception that are considered medically acceptable for the duration of the trial treatment and, if randomised to chemotherapy, for 6 months post-end of treatment if sexually active with a female of child-bearing potential.
    •Patients must be able to provide study-specific informed consent.
    •Age 18 or over
    See protocol for full criteria
    E.4Principal exclusion criteria
    • Pregnant (positive pregnancy test) or lactating.
    • Critical normal brain structures treated above usual tolerance during initial radiotherapy (i.e. based on 30 fractions initial treatment, >55Gy delivered to 1% or 0.1cm3 of optic nerve or chiasm or >55Gy delivered to >1cm3 of brainstem or >57Gy delivered to >0.1cm3 of brainstem or >50Gy to 1% or 0.1cm3 of globes).
    • Recurrence with leptomeningeal disease or only leptomeningeal disease.
    • Recurrence defined by non-enhancing disease only.
    • More than three enhancing lesions present on MRI or multi-focal recurrence.
    • IDH1/2 mutant tumours on original pathology (to avoid unbalance between arms).
    • GBM with known features of PXA, BRAF mutations or 1p19q co-deletion (on original pathology or updated pathology if available)
    • Prior invasive malignancy (except non-melanomatous skin cancer), unless disease free for a minimum of one year.
    • Severe active co-morbidity making patient unsuitable for chemotherapy or re-irradiation (e.g. uncontrolled diabetes, uncontrolled hypertension).
    • Prior allergic reaction to nitrosoureas.
    • Coeliac disease.
    • Any recognised genetic syndrome causing sensitivity to radiotherapy.
    • Patient unwilling/ unable to attend for follow up in the radiotherapy centre.
    • Contraindication to MRI or gadolinium.
    • Previous radiotherapy dose distribution unavailable.
    • Previous systemic therapy or re-irradiation for recurrent GBM.
    E.5 End points
    E.5.1Primary end point(s)
    The primary outcome measure is overall survival rate at 9 months.
    E.5.1.1Timepoint(s) of evaluation of this end point
    The assessment of the primary endpoint is based on the 9-month overall survival rates i.e. the number and proportion of patients alive in the re-irradiation arm at 9 months post-start of treatment. Overall survival is defined from randomisation to the date of death from any cause and survival data will be collected at all standard follow-up visits.
    E.5.2Secondary end point(s)
    Health Related Quality of Life (HRQOL)

    Questionnaires to be completed by participants include the European Organisation for Research and Treatment of Cancer (EORTC) Quality of life questionnaire core 30 (QLQ-C30) and Brain Cancer module (BN20). These will be completed independently by participants at clinic visits at baseline and at 6 weekly intervals post start of treatment up to 48 weeks post-start of treatment.

    In addition HRQOL will be evaluated through one-off semi-structured qualitative interviews in patient/carer subset (n~15 or until data saturation). This will include HRQOL before/ during treatment, experience of treatment and what matters most to patients/carers.

    Dexamethasone use

    Dexamethasone use will be defined by the dose and frequency of dexamethasone received. Data on dexamethasone use, including dose, any change in dose including the date of change will be collected at baseline and then on a 6 weekly basis post start of treatment.

    Anti-epileptic drug use

    Anti-epileptic drug use will be defined by the type, dose and frequency of anti-epileptic received. Data on anti- epileptic use including name of anti-epileptic drug(s), dose, any change in dose including the date of change will be collected at baseline and then on a 6 weekly basis post start of treatment.

    Radiological response rate

    Participants will be assessed for response to treatment at 12 weeks post start of treatment and then at 12 weekly intervals up to 48 weeks post start of treatment or until progression. Radiological response to treatment will be assessed via MRI imaging in accordance with Response Assessment in Neuro-Oncology (RANO) criteria.

    Acute and late toxicities

    Assessment of toxicities will take place at 6 weekly intervals post start of treatment up to 48 weeks or until progression. They will be evaluated according to the current NCI-CTCAE criteria and include all AEs. Acute toxicities will be defined as those occurring up to 12 weeks post end of treatment. Late toxicities will be defined as those occurring after 12 weeks post end of treatment. The end of treatment will be the date of the last radiotherapy dose or the final chemotherapy cycle. The period of collection of acute toxicity data will differ between arms due to different treatment lengths, but the overall period of data collection for toxicities will be the same for both treatment arms.

    Participant reported toxicities will be captured via the EORTC QLQ-C30 and QLQ-BN20 at baseline and every 6 weeks from the start of treatment up to 48 weeks or until progression.

    Progression free survival (PFS)

    Progression-free survival is defined as the time from randomisation to the first documented evidence of disease progression or death (from any cause). PFS includes radiological progression assessed in accordance with RANO criteria and non RANO evaluable progression where RANO assessment is not possible (e.g. clinical progression in a patient who is too unwell for further imaging).

    Overall survival (OS)

    Overall survival is calculated as the time from randomisation to date of death from any cause, or date last known to be alive. Patients not known to have died at the time of analysis will be censored at the date last known to be alive. Date of death or date last known to be alive will be collected throughout the trial, and from sites at the end of the trial for all participants not known to have died prior to the end of follow up.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Health Related Quality of Life HRQOL
    Evaluated at each follow up time point

    Dexamethasone use
    Evaluated at 6, 12 and 18 weeks post start of treatment and overall at the end of follow up. Evaluated over treatment period for the re-irradiation arm.

    Anti-epileptic use
    Evaluated at 6, 12 and 18 weeks post start of treatment and overall at end of follow up.

    Radiological response rate
    Evaluated at baseline, 12, 24, 36 and 48 weeks post start of treatment

    Acute and late toxicities
    Acute toxicities evaluated within 12 weeks of treatment, late toxicities >12 weeks following treatment and overall

    PFS
    Evaluated 48 weeks post start of treatment, presented for 6, 9 and 12 months post start of treatment and overall

    OS
    Evaluated at end of trial
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic No
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) Yes
    E.7.3Therapeutic confirmatory (Phase III) No
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Yes
    E.8.2.3.1Comparator description
    Re-Irradiation
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned16
    E.8.5The trial involves multiple Member States No
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA No
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    The end of the trial is defined as the date of the collection of the last participant’s data item. All evaluable trial participants will be followed up until this point. Follow-up data will be collected from sites until 48 weeks post start of treatment. A final data sweep to gather up to date survival data and information regarding additional treatments will be sent by email after the last patient has reached one year after randomisation to the trial.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years3
    E.8.9.1In the Member State concerned months4
    E.8.9.1In the Member State concerned days1
    E.8.9.2In all countries concerned by the trial years3
    E.8.9.2In all countries concerned by the trial months7
    E.8.9.2In all countries concerned by the trial days1
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1Number of subjects for this age range: 0
    F.1.1.1In Utero No
    F.1.1.1.1Number of subjects for this age range: 0
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.2.1Number of subjects for this age range: 0
    F.1.1.3Newborns (0-27 days) No
    F.1.1.3.1Number of subjects for this age range: 0
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.4.1Number of subjects for this age range: 0
    F.1.1.5Children (2-11years) No
    F.1.1.5.1Number of subjects for this age range: 0
    F.1.1.6Adolescents (12-17 years) No
    F.1.1.6.1Number of subjects for this age range: 0
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 45
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 25
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations No
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception No
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state70
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 70
    F.4.2.2In the whole clinical trial 70
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    Not applicable. The intervention of chemotherapy or radiotherapy (re-irradiation) will be completed within the trial. Patients will continue to have routine clinical care as per local standard practice.
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    G.4.1Name of Organisation University of Leeds, Clinical Trials Research Unit
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2020-07-06
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2020-07-06
    P. End of Trial
    P.End of Trial StatusGB - no longer in EU/EEA
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 06 15:13:22 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA